<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Metastases</z:e> are the primary cause of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="15864">Luteolin</z:chebi>, a naturally occurring phytochemical, has chemopreventive and/or anticancer properties in several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>However, anti-metastatic effects of <z:chebi fb="0" ids="15864">luteolin</z:chebi> in vivo and the underlying molecular mechanisms and target(s) remain unknown </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="15864">Luteolin</z:chebi> suppresses matrix metalloproteinase (MMP)-2 and -9 activities and invasion in murine <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> CT-26 cells </plain></SENT>
<SENT sid="4" pm="."><plain>Western blot and kinase assay data revealed that <z:chebi fb="0" ids="15864">luteolin</z:chebi> inhibited Raf and phosphatidylinositol 3-kinase (PI3K) activities and subsequently attenuated phosphorylation of MEK and Akt </plain></SENT>
<SENT sid="5" pm="."><plain>A pull-down assay indicated that <z:chebi fb="0" ids="15864">luteolin</z:chebi> non-competitively bound with ATP to suppress Raf activity and competitively bound with ATP to inhibit PI3K activity </plain></SENT>
<SENT sid="6" pm="."><plain>GW5074, a Raf inhibitor, and LY294002, a PI3K inhibitor, inhibited MMP-2 and -9 activities and invasion in CT-26 cells </plain></SENT>
<SENT sid="7" pm="."><plain>An in vivo mouse study showed that oral administration (10 or 50 mg/kg) of <z:chebi fb="0" ids="15864">luteolin</z:chebi> significantly inhibited <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> nodules and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume of lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> induced by intravenous injection of CT-26 cells </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="15864">Luteolin</z:chebi> also inhibited MMP-9 expression and activity in CT-26-induced mouse lung tissue </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that <z:chebi fb="0" ids="15864">luteolin</z:chebi> may have considerable potential for development as an anti-metastatic agent </plain></SENT>
<SENT sid="10" pm="."><plain>Copyright © 2012 John Wiley &amp; Sons, Ltd </plain></SENT>
</text></document>